|Table of Contents|

Metformin Inhibits the Metastasis of Head and Neck Cancerby Regulating the Expression of STAT3(PDF)

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

Issue:
2019年01期
Page:
107-
Research Field:
·生命科学·
Publishing date:

Info

Title:
Metformin Inhibits the Metastasis of Head and Neck Cancerby Regulating the Expression of STAT3
Author(s):
Wu Dandan; Pei Lili; Li Bingyan; Wu Xia
Kangda College of Nanjing Medical University,Department of Basic Medicine,Lianyungang 222000,China
Keywords:
metformin; STAT3; head and neck cancr; IL-6
PACS:
739.91
DOI:
10.3969/j.issn.1001-4616.2019.01.017
Abstract:
To study whether metformin can inhibit the epithelial-mesenchymal transition and migration of head and neck cancer by regulating the expression of STAT3. Metformin was given on the head and neck cancer 686LN cell line and Western blot was used to detect related protein of epithelial-mesenchymal transition(EMT). The effect of metformin on head and neck cancer cell migration was determined by transwell assay. Western blot anlaysis was used to detect the expression of STAT3 in a highly metastatic head and neck cancer cell line and a paired low metastatic cell line. STAT3 siRNA transfected in head and neck cancer to detect the effect of STAT3 on EMT. Western blot anlaysis was used to detect the expression of STAT3 and EMT related protein in 686LN cells treated with IL-6 or metformin. The effect of metformin on cell migration induced by IL-6 by transwell assay. The EMT and the cell migration ability were inhibited in 686LN cells treated with metformin. The expressin of STAT3 phosphorylation and total protein in high level in the highly metastatic head and neck cancer cell line. Transfection of STAT3 siRNA inhibited the expression of STAT3 could inhibit the EMT of head and neck cancer. Metformin inhibited IL-6 mediated STAT3 phosphorylation and inhibits IL-6 induced EMT,while metformin inhibited IL-6 induced cell migration. The results showed that,metformin inhibited EMT and cell migration,and can inhibit IL-6 mediated STAT3 phosphorylation in head and neck cancer,which inhibited the metastasis of head and neck cancer may be related to the downregulation of the phosphorylation level of STAT3.

References:

[1] BAUR D M,KLOTSCHE J,HAMNVIK O P,et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort[J]. Metabolism:clinical and experimental,2011,60(10):1363-1371.
[2]CHEN T W,LIANG Y N,FENG D,et al. Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90[J]. Journal of BUON:official journal of the Balkan Union of Oncology,2013,18(1):51-56.
[3]朱智峰,梁琳琅. 二甲双胍对结肠癌细胞增殖、周期及凋亡的影响[J]. 中国医科大学学报,2012,41(2):51-56.
[4]薛知新,钟捷,赵丹瑜,等. 二甲双胍对AGS胃癌细胞生长侵袭的抑制作用[J]. 世界华人消化杂志,2010,18(19):1974-1978.
[5]SIVEEN K S,SIKKA S,SURANA R,et al. Targeting the STAT3 signaling pathway in cancer:role of synthetic and natural inhibitors[J]. Biochimica et biophysica acta,2014,1845(2):136-154.
[6]ZHANG X,ZHANG J,WEI H,et al. STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes[J]. Oncology reports,2007,17(6):1377-1382.
[7]DARNELL J E. STATs and gene regulation[J]. Science,1997,277(5332):1630-1635.
[8]WANG X H,LIU B R,QU B,et al. Silencing STAT3 may inhibit cell growth through regulating signaling pathway,telomerase,cell cycle,apoptosis and angiogenesis in hepatocellular carcinoma:potential uses for gene therapy[J]. Neoplasma,2011,58(2):158-171.
[9]BOLLRATH J,PHESSE T J,VON BURSTIN V A,et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis[J]. Cancer cell,2009,15(2):91-102.
[10]KIUCHI N,NAKAJIMA K,ICHIBA M,et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene[J]. Journal of experimental medicine,1999,189(1):63-73.
[11]ASGEIRSSON K S,OLAFSDOTTIR K,JONASSON J G,et al. The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer[J]. Cytokine,1998,10(9):720-728.
[12]杨佳华,刘颖斌,董平. 上皮间质细胞转化与肿瘤细胞侵袭转移的关系[J]. 中华医学杂志,2011,91(8):572-574.
[13]ZHAO Z,CHENG X,WANG Y,et al. Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis[J]. PloS one,2014,9(4):e95884.
[14]KASTRITIS E,CHARIDIMOU A,VARKARIS A,et al. Targeted therapies in multiple myeloma[J]. Targeted oncology,2009,4(1):23-36.
[15]WU D,CHENG J,SUN G,et al. p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma[J]. Oncotarget,2016,7(24):36539-36550.
[16]IWATSUKI M,MIMORI K,YOKOBORI T,et al. Epithelial-mesenchymal transition in cancer development and its clinical significance[J]. Cancer science,2010,101(2):293-299.
[17]BAILEY C J,TURNER R C. Metformin[J]. The New England journal of medicine,1996,334(9):574-579.
[18]SIKKA A,KAUR M,AGARWAL C,et al. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation[J]. Cell cycle,2012,11(7):1374-1382.

Memo

Memo:
-
Last Update: 2019-03-30